1What are the two consistency problems with structural explanations of schizophrenia?
Lack of replicability: structural findings do not consistently recur across studies
Consistency across patients: group-level differences ≠ the same abnormality in every individual
2Which review supports enlarged ventricles as an indicator; & what qualification must follow?
McCarley et al. (1999): enlarged ventricles described as the most reliable physical indicator
BUT findings vary: structural abnormalities are not consistently reproduced across all diagnosed individuals
3Which three patient variables may help explain inconsistent structural findings?
Patient variables: age; sex & symptom severity
Influence what is seen: the prevalence & pattern of brain damage can vary with these characteristics
4What conclusion should you draw from inconsistent structural findings across patients?
Not universal: brain-structure changes cannot be assumed in every patient
Researchers need to account for: individual participant variables
More precise detection: needed to examine subtle anatomical differences; does not itself establish causation
5What does lack of replicability mean here?
Structural findings do not consistently recur across studies. Distinguish this from individual variability: a group-level difference does not mean every patient has the same abnormality.
6Evaluate structural explanations: Replicability & consistency.
1. Firstly: the research problem
Lack of replicability: structural findings do not consistently recur across studies
Consistency across patients: group-level differences ≠ the same abnormality in every individual
2. Although: supporting evidence
McCarley et al. (1999): enlarged ventricles described as the most reliable physical indicator
BUT findings vary: structural abnormalities are not consistently reproduced across all diagnosed individuals
3. Why might findings differ?
Patient variables: age; sex & symptom severity
Influence what is seen: the prevalence & pattern of brain damage can vary with these characteristics
4. This demonstrates: implication
Not universal: brain-structure changes cannot be assumed in every patient
Researchers need to account for: individual participant variables
More precise detection: needed to examine subtle anatomical differences; does not itself establish causation
7What cause-and-effect question challenges structural explanations?
Possible cause: structural abnormalities -> schizophrenia?
Possible consequence: a byproduct of living with the condition?
8Which two alternative influences may account for observed structural differences?
Environmental factors: may alter brain tissue over time
Treatment history: medication exposure may influence the observed structural differences
9Which study linked medication dosage with brain tissue density? Give the finding & limitation.
For instance: Lyon et al. (1981)
Higher doses: antipsychotic medication
Correlated with: decreased brain tissue density
Meaning: an association; it does not isolate medication as the cause
10Why can scans taken after illness onset fail to establish the primary aetiology?
Observed abnormalities: may reflect long-term medication use or illness progression
Treatment effect or artefact: a possible consequence rather than the primary aetiology
Final implication: scans taken after onset cannot; alone; establish which change came first
11What does primary aetiology mean?
The underlying origin or cause of the disorder. A structural abnormality observed after onset could instead be a consequence of illness progression or treatment.
12Evaluate structural explanations: Cause & effect.
1. Furthermore: which direction?
Possible cause: structural abnormalities -> schizophrenia?
Possible consequence: a byproduct of living with the condition?
2. Alternative influences
Environmental factors: may alter brain tissue over time
Treatment history: medication exposure may influence the observed structural differences
3. For instance: Lyon et al. (1981)
For instance: Lyon et al. (1981)
Higher doses: antipsychotic medication
Correlated with: decreased brain tissue density
Meaning: an association; it does not isolate medication as the cause
4. This suggests: causal uncertainty
Observed abnormalities: may reflect long-term medication use or illness progression
Treatment effect or artefact: a possible consequence rather than the primary aetiology
Final implication: scans taken after onset cannot; alone; establish which change came first
13What does it mean to say structural abnormalities lack diagnostic specificity? Give two examples.
Lack diagnostic specificity: structural features may occur in more than one disorder
Two examples: reduced brain volume & enlarged ventricles
14Which study reports similar structural anomalies in other disorders; & which disorders?
Roy et al. (1998)
Similar structural anomalies: reported in bipolar disorder & schizoaffective disorder
Overlapping symptom profiles: the disorders also share some clinical features
15Why does an abnormal brain scan not automatically identify schizophrenia?
Not exclusive to schizophrenia: an abnormal scan does not automatically identify this diagnosis
Distinguishing disorders: requires evidence about the subtle differences; not just shared abnormalities
16What judgement follows about structural scans & differential diagnosis?
Structural scans alone: cannot provide a definitive differential diagnosis of schizophrenia
Precise conclusion: associated brain features can inform research without being a unique diagnostic test
17Distinguish diagnostic specificity from differential diagnosis.
Diagnostic specificity concerns whether a feature distinguishes the target disorder from other conditions. Differential diagnosis involves distinguishing between possible diagnoses; a shared abnormality alone cannot do this.
18Evaluate structural explanations: Diagnostic specificity.
1. In addition: the limitation
Lack diagnostic specificity: structural features may occur in more than one disorder
Two examples: reduced brain volume & enlarged ventricles
2. Roy et al. (1998)
Roy et al. (1998)
Similar structural anomalies: reported in bipolar disorder & schizoaffective disorder
Overlapping symptom profiles: the disorders also share some clinical features
3. Why this matters for scanning
Not exclusive to schizophrenia: an abnormal scan does not automatically identify this diagnosis
Distinguishing disorders: requires evidence about the subtle differences; not just shared abnormalities
4. Therefore: diagnostic usefulness
Structural scans alone: cannot provide a definitive differential diagnosis of schizophrenia
Precise conclusion: associated brain features can inform research without being a unique diagnostic test
Precision note: the original “current technology is not yet sophisticated enough” claim is time-sensitive; the map focuses on diagnostic specificity.
19What are the two competing accounts of when structural abnormalities develop?
Neurodevelopmental? = early disruption in the development of the brain
Neurodegenerative? = progressive loss or deterioration after illness onset
20How do developmental & degenerative influences differ in their timing?
Developmental influences: exposure to noxious agents in utero; during childhood or adolescence
Degenerative influences: progressive post-onset brain tissue loss
21Who proposed a dual-process account; & how does it reconcile the two explanations?
To reconcile: Mathalon (2003)
Dual-process model: both processes can contribute
Early vulnerability: neurodevelopmental vulnerability
Subsequent change: later neurodegenerative decline
22Why might a purely structural account be reductionist?
Purely structural lens: a static picture can miss development & change
Oversimplifies: a complex; evolving neurobiological process
Overall judgement: consider how early vulnerability & later changes combine
23Distinguish neurodevelopmental from neurodegenerative.
Neurodevelopmental = early disruption in brain development. Neurodegenerative = progressive loss or deterioration; the map discusses decline after illness onset. A dual-process model allows both to contribute.
24Evaluate structural explanations: Development & degeneration.
1. Finally: an ongoing debate
Neurodevelopmental? = early disruption in the development of the brain
Neurodegenerative? = progressive loss or deterioration after illness onset
2. It remains unclear: timing
Developmental influences: exposure to noxious agents in utero; during childhood or adolescence
Degenerative influences: progressive post-onset brain tissue loss
3. To reconcile: Mathalon (2003)
To reconcile: Mathalon (2003)
Dual-process model: both processes can contribute
Early vulnerability: neurodevelopmental vulnerability
Subsequent change: later neurodegenerative decline
4. Consequently: reductionism
Purely structural lens: a static picture can miss development & change
Oversimplifies: a complex; evolving neurobiological process
Overall judgement: consider how early vulnerability & later changes combine